4 completed, 2 recruiting, 2 withdrawn, 1 unknown. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Recruiting 2, Withdrawn 2, Unknown 1 |
| Phase 2 | 4 | Withdrawn 2, Completed 1, Unknown 1 |
Follow Peripheral Nerve Injuries: new trials by email Literature Review of Peripheral Nerve Injuries trials Research Report on Peripheral Nerve Injuries
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of ASCT-83 in Healthy Adults ASCT-83, Placebo - Neuropathic Pain | Phase 1 | Recruiting | Alcamena Stem Cell Therapeutics | 72 | 2026-01-06 | 2026-06-16 |
| Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI) Autologous Human Schwann Cell - Peripheral Nerve Injury | Phase 1 | Recruiting | W. Dalton Dietrich | 30 | 2023-05-04 | 2026-09-29 |
| Polyethylene Glycol to Improve Sensation Following Digital Nerve Laceration Polyethylene Glycol 3350, Normal Saline - Peripheral Nerve Injury, Nerve Injury | Phase 1 / Phase 2 | Withdrawn | Nova Scotia Health Authority | 2020-06-26 | 2024-01-05 | |
| Autologous Human Schwann Cells in Peripheral Nerve Repair autologous human Schwann cells - Peripheral Nerve Injuries | Phase 1 | Completed | W. Dalton Dietrich | 5 | 2019-09-24 | 2025-12-12 |
| Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function Polyethylene glycol (PEG) - Peripheral Nerve Injury | Phase 1 | Completed | Vanderbilt University Medical Center | 45 | 2019-09-19 | 2026-06-15 |
| Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury Neovasculgen - Peripheral Nerve Injury | Phase 1 / Phase 2 | Unknown | Artgen Biotech | 45 | 2015-04-01 | 2015-02-02 |
| Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus Tacrolimus - Peripheral Nerve Injury | Phase 1 / Phase 2 | Withdrawn | Washington University School of Medicine | 2010-08-01 | 2018-02-13 | |
| Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain CAPNP, 50 ug/cm2 capsaicin patch, CAPNP, 100 ug/cm2 capsaicin patch, 0.075% capsaicin cream - Peripheral Nerve Injury, Postherpetic Neuralgia | Phase 1 / Phase 2 | Completed | Samyang Biopharmaceuticals Corporation | 60 | 2009-02-01 | 2017-05-01 |
| GW406381 In Patients With Peripheral Nerve Injury GW406381 - Hyperalgesia, Neurodynia | Phase 1 | Completed | GlaxoSmithKline | 40 | 2003-09-01 | 2009-02-23 |
Neuralgia (2) · Hyperalgesia (1) · Neuralgia, Postherpetic (1) · Pain (1) · Trauma, Nervous System (1) · Wounds and Injuries (1)
Nervous System Diseases (9) · Neuromuscular Diseases (9) · Peripheral Nervous System Diseases (9) · Trauma, Nervous System (8) · Wounds and Injuries (8) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Pain (2) · Neuralgia (1) · Sensation Disorders (1) · Somatosensory Disorders (1)
GW406381X (1) · Polyethylene Glycols (1) · Saline Solution (1) · Tacrolimus (1) · polyethylene glycol 3350 (1)
W. Dalton Dietrich (2) · Alcamena Stem Cell Therapeutics (1) · Artgen Biotech (1) · GlaxoSmithKline (1) · Nova Scotia Health Authority (1) · Samyang Biopharmaceuticals Corporation (1) · Vanderbilt University Medical Center (1) · Washington University School of Medicine (1)
United States (4) · South Korea (1) · United Kingdom (1)
Allan Levi, MD, PhD (1) · Edmund Nesti, PhD (1) · Thomas H Tung, MD (1) · Trisha Shamp, PhD, PA-C, ECG-BA, CVPA-BC (1) · W. Dalton Dietrich, MD (1) · Wesley Thayer, MD (1)
R44NS145934 (1)